Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 3/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11796135 | 0.91 | AOC2 (0.66) | AOC2AOC3CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL14820608 | 0.83 | HDAC6 (0.63) | CYP3A4CYP1A2CNR2GLSSIGMAR1 | |
| SCHEMBL27099071 | 0.83 | AOC2 (0.61) | AOC2AOC3CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL2492150 | 0.83 | CA2 (0.59) | AOC2AOC3CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL27633225 | 0.83 | AOC2 (0.58) | AOC2AOC3CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL934891 | 0.81 | AOC2 (0.64) | AOC2AOC3CNR2ALDH1A1 | |
| SCHEMBL12941833 | 0.81 | AOC2 (0.56) | AOC2AOC3 | |
| SCHEMBL754150 | 0.81 | GAA (0.63) | AOC2AOC3ALDH1A1TDP1 | |
| SCHEMBL965837 | 0.81 | LMNA (0.59) | AOC2CNR2ALDH1A1 | |
| SCHEMBL12597427 | 0.81 | AOC2 (0.56) | AOC2AOC3CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161296-A1 | CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN | ADC THERAPEUTICS SA (CH) | 2023-08-31 | — | — | WO | disclosed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | AOC2 3782/4885AOC3 3507/4885CYP3A4 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.